Effectiveness of mass oral cholera vaccination in Beira, Mozambique - PubMed
- ️Sat Jan 01 2005
. 2005 Feb 24;352(8):757-67.
doi: 10.1056/NEJMoa043323.
Jacqueline L Deen, Lorenz von Seidlein, Xuan-Yi Wang, Julia Ampuero, Mahesh Puri, Mohammad Ali, M Ansaruzzaman, Juvenaldo Amos, Arminda Macuamule, Philippe Cavailler, Philippe J Guerin, Claude Mahoudeau, Pierre Kahozi-Sangwa, Claire-Lise Chaignat, Avertino Barreto, Francisco F Songane, John D Clemens
Affiliations
- PMID: 15728808
- DOI: 10.1056/NEJMoa043323
Free article
Effectiveness of mass oral cholera vaccination in Beira, Mozambique
Marcelino E S Lucas et al. N Engl J Med. 2005.
Free article
Abstract
Background: New-generation, orally administered cholera vaccines offer the promise of improved control of cholera in sub-Saharan Africa. However, the high prevalence of human immunodeficiency virus (HIV) infection in many cholera-affected African populations has raised doubts about the level of protection possible with vaccination. We evaluated a mass immunization program with recombinant cholera-toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in Beira, Mozambique, a city where the seroprevalence of HIV is 20 to 30 percent.
Methods: From December 2003 to January 2004, we undertook mass immunization of nonpregnant persons at least two years of age, using a two-dose regimen of rBS-WC vaccine in Esturro, Beira (population 21,818). We then assessed vaccine protection in a case-control study during an outbreak of El Tor Ogawa cholera in Beira between January and May 2004. To estimate the level of vaccine protection, antecedent rates of vaccination were compared between persons with culture-confirmed cholera severe enough to have prompted them to seek treatment and age- and sex-matched neighborhood controls without treated diarrhea.
Results: We assessed the effectiveness of the vaccine in 43 persons with cholera and 172 controls. Receipt of one or more doses of rBS-WC vaccine was associated with 78 percent protection (95 percent confidence interval, 39 to 92 percent; P=0.004). The vaccine was equally effective in children younger than five years of age and in older persons. A concurrently conducted case-control study designed to detect bias compared persons with treated, noncholeraic diarrhea and controls without diarrhea in the same population and found no protection associated with receipt of the rBS-WC vaccine.
Conclusions: The rBS-WC vaccine was highly effective against clinically significant cholera in an urban sub-Saharan African population with a high prevalence of HIV infection.
Copyright 2005 Massachusetts Medical Society.
Comment in
-
Disaster, water, cholera, vaccines, and hope.
Drazen JM, Klempner MS. Drazen JM, et al. N Engl J Med. 2005 Feb 24;352(8):827. doi: 10.1056/NEJMe058031. N Engl J Med. 2005. PMID: 15728816 No abstract available.
Similar articles
-
Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA. Concha A, et al. Bull Pan Am Health Organ. 1995 Dec;29(4):312-21. Bull Pan Am Health Organ. 1995. PMID: 8605522 Clinical Trial.
-
Murray J, McFarland DA, Waldman RJ. Murray J, et al. Bull World Health Organ. 1998;76(4):343-52. Bull World Health Organ. 1998. PMID: 9803585 Free PMC article.
-
Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, Hung NV, Canh DG, Thiem VD, Naficy A, Ivanoff B, Svennerholm AM, Holmgren J, Clemens JD. Trach DD, et al. Bull World Health Organ. 2002;80(1):2-8. Bull World Health Organ. 2002. PMID: 11884967 Free PMC article. Clinical Trial.
-
A review of the current status of enteric vaccines.
Levine MM, Noriega F. Levine MM, et al. P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.
-
Oral vaccines for cholera control.
Chaturvedi S, Chaturvedi S. Chaturvedi S, et al. Natl Med J India. 1997 Jan-Feb;10(1):17-8. Natl Med J India. 1997. PMID: 9069701 Review.
Cited by
-
Deen J, Clemens JD. Deen J, et al. Trop Med Infect Dis. 2021 Mar 9;6(1):32. doi: 10.3390/tropicalmed6010032. Trop Med Infect Dis. 2021. PMID: 33803390 Free PMC article. Review.
-
Safety of live, attenuated oral vaccines in HIV-infected Zambian adults: oral vaccines in HIV.
Banda R, Yambayamba V, Lalusha BD, Sinkala E, Kapulu MC, Kelly P. Banda R, et al. Vaccine. 2012 Aug 17;30(38):5656-60. doi: 10.1016/j.vaccine.2012.06.079. Epub 2012 Jul 10. Vaccine. 2012. PMID: 22789509 Free PMC article.
-
Optimizing one-dose and two-dose cholera vaccine allocation in outbreak settings: A modeling study.
Leung T, Eaton J, Matrajt L. Leung T, et al. PLoS Negl Trop Dis. 2022 Apr 20;16(4):e0010358. doi: 10.1371/journal.pntd.0010358. eCollection 2022 Apr. PLoS Negl Trop Dis. 2022. PMID: 35442958 Free PMC article.
-
Cholera toxin B: one subunit with many pharmaceutical applications.
Baldauf KJ, Royal JM, Hamorsky KT, Matoba N. Baldauf KJ, et al. Toxins (Basel). 2015 Mar 20;7(3):974-96. doi: 10.3390/toxins7030974. Toxins (Basel). 2015. PMID: 25802972 Free PMC article. Review.
-
Wiens KE, Xu H, Zou K, Mwaba J, Lessler J, Malembaka EB, Demby MN, Bwire G, Qadri F, Lee EC, Azman AS. Wiens KE, et al. PLoS Med. 2023 Sep 14;20(9):e1004286. doi: 10.1371/journal.pmed.1004286. eCollection 2023 Sep. PLoS Med. 2023. PMID: 37708235 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical